Business Context and Reporting Period
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 23, 2023
Reporting Period: Event date January 23, 2023
On January 23, 2023, Iovance Biotherapeutics, Inc. entered into a material definitive agreement to acquire worldwide rights in Proleukin (aldesleukin) from Clinigen Holdings Limited and affiliates. The transaction is expected to close in the first quarter of 2023, subject to regulatory approvals.
Key Financial Metrics
| Metric | Value |
|---|---|
| Unaudited Cash Position (as of Jan 20, 2023) | $477.0 million |
| Upfront Payment for Acquisition | £167.7 million (approx. $200 million) |
| Milestone Payment (upon lifileucel approval) | £41.7 million (approx. $50 million) |
| Deferred Consideration | Double-digit rates on global net sales |
| Proposed Line of Credit | Up to $100.0 million (Non-binding) |
| Proposed Credit Interest Rate | SOFR + 8.50% (Floor: 12.5%) |
| Proposed Facility Fee | $3.0 million |
Note: This filing does not provide revenue, profit, cash flow, or margin data for a specific reporting period.
Material Changes and Transactions
- Acquisition of Proleukin: The Company agreed to acquire worldwide rights, manufacturing, supply, and commercialization operations for Proleukin (aldesleukin).
- Financing Structure: The acquisition is being financed with existing cash. The Company raised approximately $227.1 million via an at-the-market (ATM) equity facility in Q4 2022 and early 2023.
- Call and Put Options: The agreement includes a call option for the Company to purchase all shares of Clinigen SP Limited and a put option for the Sellers to sell the business.
- Proposed Credit Facility: The Company agreed to non-binding terms for a secured line of credit of up to $100 million from Quogue Capital LLC. This is a related-party transaction as Wayne Rothbaum, a Company director, is the sole owner of Quogue Capital LLC.
Outlook, Risks, and Contingencies
- Closing Conditions: The acquisition is subject to customary closing conditions, including regulatory approvals and clearances.
- Termination Fees: The agreement includes customary termination provisions, including a reverse termination fee payable to Sellers upon certain events.
- Related Party Transaction: The proposed line of credit involves a director of the Company. The director recused himself from Board deliberations, and the Audit Committee will approve the definitive agreement.
- Non-Binding Terms: The proposed line of credit is non-binding and subject to the execution of a definitive agreement.
Investor Verification Checklist
- Verify the final closing date of the Proleukin acquisition and confirmation of regulatory approvals.
- Confirm the execution of the definitive agreement for the $100 million line of credit and final interest rate terms.
- Monitor the Company's cash burn rate post-acquisition given the $200 million upfront payment.
- Review the definitive agreement for the specific definition of "global net sales" for deferred consideration calculations.
- Check for any updates regarding the milestone payment trigger for lifileucel approval in advanced melanoma.